70839 Origami™ B(DE3)pLysS Competent Cells - Novagen

70839
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service
      View Pricing & Availability

      Overview

      Replacement Information

      Pricing & Availability

      Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
      70839-3
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service
          Contact Customer Service

          Plastic ampoule 0.4 ml
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          70839-4
          Retrieving availability...
          Limited AvailabilityLimited Availability
          Stocked 
          Discontinued
          Limited Quantities Available
          Available
            Remaining : Will advise
              Remaining : Will advise
              Will advise
              Contact Customer Service
              Contact Customer Service

              Glass bottle 1 ml
              Retrieving price...
              Price could not be retrieved
              Minimum Quantity needs to be mulitiple of
              Upon Order Completion More Information
              You Saved ()
               
              Request Pricing
              Description
              OverviewOrigami™ B host strains carry the same mutations in trxB and gor as the original Origami strains, except that they are derived from a lacZY mutant of BL21 to enable precise control of expression levels by adjusting the concentration of IPTG. Thus the Origami B strains combine the desirable characteristics of BL21, Tuner™, and Origami strains in one strain background. The mutations in trxB and gor are selectable on kanamycin and tetracycline, respectively; therefore, these strains cannot be used with plasmids that can only selected with kanamycin or tetracycline. These strains also include the lon and ompT deficiences of BL21, which increase protein stability.

              DE3 indicates that the host is a lysogen of λDE3, and therefore carries a chromosomal copy of the T7 RNA polymerase gene under control of the lacUV5 promoter. Such strains are suitable for production of protein from target genes cloned in pET vectors by induction with IPTG.

              pLysS strains express T7 lysozyme, which further suppresses basal expression of T7 RNA polymerase prior to induction, thus stabilizing pET recombinants encoding target proteins that affect cell growth and viability.
              Genotype: F- ompT hsdSB(rB- mB-) gal dcm lacY1 ahpC (DE3) gor522:: Tn10 trxB pLysS (CamR, KanR, TetR)


              This product contains genetically modified organisms (GMO). Within the EU GMOs are regulated by Directives 2001/18/EC and 2009/41/EC of the European Parliament and of the Council and their national implementation in the member States respectively. This legislation obliges MilliporeSigma to request certain information about you and the establishment where the GMOs are being handled. Click here for Enduser Declaration (EUD) Form.




              This product is sold for internal research use only. Any commercial use of this product, its components, and/or any derivatives thereof (including but not limited to proteins produced using the product or its components) (together and hereinafter the 'EMD Product') requires signature of a written commercial use agreement with EMD Millipore Corporation or its successor-in-interest. Commercial use shall include but not be limited to: (1) use of the EMD Product to manufacture products for sale to third parties; (2) use of the EMD Product to provide services, information, or data to third parties in exchange for consideration; (3) use of the EMD Product for therapeutic, diagnostic or prophylactic purposes (including as part of a device, chip, assay or other product); or (4) resale of the EMD Product, whether or not such EMD Product is resold for research use. Nothing contained herein shall be deemed to represent or warrant that additional third party rights are not required for use of the EMD Product. Please direct any questions on these use restrictions to: licensing@milliporesigma.com.
              Catalogue Number70839
              Brand Family Novagen®
              References
              Product Information
              Components
              Guaranteed efficiencyGuaranteed efficiency: > 2 x 10⁶ cfu/μg
              Applications
              Biological Information
              Physicochemical Information
              Dimensions
              Materials Information
              Toxicological Information
              Safety Information according to GHS
              Safety Information
              Product Usage Statements
              Storage and Shipping Information
              Ship Code Dry Ice Only
              Toxicity Multiple Toxicity Values, refer to MSDS
              Storage ≤ -70°C
              Do not freeze Ok to freeze
              Packaging Information
              Transport Information
              Supplemental Information
              Specifications

              Documentation

              Origami™ B(DE3)pLysS Competent Cells - Novagen SDS

              Title

              Safety Data Sheet (SDS) 

              Origami™ B(DE3)pLysS Competent Cells - Novagen Certificates of Analysis

              TitleLot Number
              70839

              Citations

              Title
            • Megan M. Kibbey, et al. (2006) Insulin-like growth factor binding protein-2: contributions of the C-terminal domain to IGF-1 binding. Molecular Pharmacology 69, 833-845.
            • James Flint, et al. (2005) Probing the mechanism of ligand recognition in family 29 carbohydrate-binding molecules. Journal of Biological Chemistry 280, 23718-23726.
            • Related Products & Applications

              Related Products

              Catalog Number Description  
              70836 Origami™ B Competent Cells - Novagen Show Pricing & Availability
              70837 Origami™ B(DE3) Competent Cells - Novagen Show Pricing & Availability
              70911 Origami™ B Competent Cell Set - Novagen Show Pricing & Availability

              Related Products By: Brand Facete

              Categories

              Life Science Research > Genomic Analysis > Transfection and Protein Expression > Bacterial Expression > Competent Cells for Expression